J Korean Soc Pediatr Endocrinol.  2011 Apr;16(1):20-23. 10.6065/jkspe.2011.16.1.20.

Serum IGF-1 and IGFBP-3 Levels in Central Precocious Puberty Girls Treated with Gonadotropin Releasing Hormone Agonist (GnRHa)

• Yi KH

• KMID: 1450619
• DOI: http://doi.org/10.6065/jkspe.2011.16.1.20

Abstract

PURPOSE
The purpose of this test was to investigate the changes of serum IGF-1 and IGFBP-3 levels during a one-year gonadotropin releasing hormone agonist (GnRHa) treatment in central precocious puberty (CPP) girls.
METHODS
From 2007 to 2009, 26 girls were enrolled in this study. They were diagnosed as having central precocious puberty and were treated with GnRHa (leuprolide actete) for one year. Their height, bone age, and serum IGF-1 and IGFBP-3 levels were evaluated every six months.
RESULTS
At the time of diagnosis, their mean serum IGF-1 and IGFBP-3 levels were 302.90+/-102.54 ng/mL and 3,103.58+/-705.08 ng/mL, respectively. At six month after treatment, the serum IGF-1 and IGFBP-3 levels were slightly decreased. One year later, IGF-1 concentrations were higher than before treatment and IGFBP-3 levels were lower (P=NS). This result, however, was not statistically significant.
CONCLUSION
Gonadal suppression with gonadotropin releasing hormones inversely influenced circulating IGF-1 and IGFBP-3 levels. However, the serum IGF-1 and IGFBP-3 levels were maintained at relatively steady levels, preserving a normal height velocity.

Keyword

Puberty, precocious; Gonadotropin releasing hormone agonist; Insulin-like growth factor-1; Insulin-like growth factor binding protein-3

MeSH Terms

Gonadotropin-Releasing Hormone
Gonadotropins
Gonads
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Puberty, Precocious
Gonadotropin-Releasing Hormone
Gonadotropins
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I